Virtual event on Wednesday, September 7 at 4:30 PM ET will feature key opinion leader (KOL) David Hong, M.D., from MD Anderson Cancer Center
Company to present preliminary clinical data and future directions for its lead clinical candidates with best-in-class potential, ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601
SAN DIEGO, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it will host a research and development day, with a focus on the company’s ERAS-007 ERK1/2 inhibitor and ERAS-601 SHP2 inhibitor in advanced solid tumors, on Wednesday, September 7, 2022, at 4:30 PM Eastern Time.
The virtual event will feature presentations from:
Key opinion leader David S. Hong, M.D., of MD Anderson Cancer Center, who will provide an overview of the current treatment landscape and therapeutic opportunities in cancers driven by the RAS/MAPK pathway and will discuss Erasca’s lead programs in this context.
Erasca, who will present preliminary clinical data and future directions for its lead clinical candidates with best-in-class potential, ERAS-007 and ERAS-601, for the treatment of advanced solid tumors with RAS/MAPK pathway alterations.
A live question and answer session will follow. To register for the event, please click here.
David S. Hong, M.D., serves as deputy chair in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center in Houston, Texas. Dr. Hong earned his medical degree from Albert Einstein College of Medicine in 1999, following his undergraduate studies in oncology at Yale University. He completed his residency at Thomas Jefferson University Hospital and his fellowship in medical oncology at MD Anderson Cancer Center, where he was appointed Chief Medical Oncology Fellow. Dr. Hong has received several awards, including the Amgen Young Investigator Award, the Jesse H. Jones Award, and the Goodwin Funding Award, for his research in drug development studying the molecular basis of cancer.
About ERAS-007 ERAS-007 is a potential best-in-class oral, selective ERK1/2 inhibitor being investigated alone or in combination with different inhibitors targeting upstream nodes of the MAPK pathway as part of Erasca’s MAPKlamp strategy. The extracellular signal-regulated kinases (ERK), ERK1 and ERK2, belong to a family of serine-threonine kinases that regulate cellular signaling and comprise the terminal node of the RAS/MAPK pathway. The broad therapeutic potential of ERAS-007 is being investigated initially across a series of HERKULES clinical trials that span multiple tumor types and include both monotherapy and combinations with approved and investigational agents, such as RTK, SHP2, RAS, RAF, and/or cell cycle inhibitors. HERKULES-1 is a Phase 1b/2 clinical trial for ERAS-007 as a single agent and in combination with the SHP2 inhibitor ERAS-601 (together, Erasca’s first MAPKlamp combination) in advanced solid tumors. HERKULES-2 is a Phase 1b/2 master protocol for ERAS-007 in combination with various agents in patients with NSCLC. HERKULES-3 is a Phase 1b/2 master protocol for ERAS-007 in combination with various agents in patients with GI cancers.
About ERAS-601 ERAS-601 is a potential best-in-class oral, selective SHP2 inhibitor being investigated alone or in combination. SHP2 acts as a convergent node for receptor tyrosine kinase (RTK) signaling, relaying growth and survival signals from RTKs to intracellular signaling pathways. ERAS-601 is being investigated across a series of clinical trials that span multiple tumor types and include both monotherapy and combinations with approved and investigational agents. FLAGSHP-1 is a Phase 1/1b dose escalation trial evaluating ERAS-601 as a monotherapy in advanced solid tumors and in combination in triple wildtype CRC and HPV-negative advanced HNSCC. HERKULES-2 is a Phase 1b/2 master protocol clinical trial that includes evaluation of ERAS-601 in combination with various agents in patients with NSCLC.
About Erasca At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Cautionary Note Regarding Forward-Looking Statements Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the potential therapeutic benefits of our product candidates and the potential patient populations for our product candidates and development programs, including ERAS-007 and ERAS-601; and the planned advancement of our development pipeline, including the clinical development plans for the HERKULES series of trials and the FLAGSHP-1 trial. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our approach to the discovery and development of product candidates based on our singular focus on shutting down the RAS/MAPK pathway, a novel and unproven approach; delays in our preclinical and clinical development programs; our dependence on third parties to conduct manufacturing, research, and preclinical and clinical testing; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval, and/or commercialization, or may result in recalls or product liability claims; unfavorable results from preclinical studies or clinical trials; results from preclinical studies or early clinical trials not necessarily being predictive of future results; regulatory developments in the United States and foreign countries; our ability to obtain and maintain intellectual property protection for our product candidates and maintain our rights under intellectual property licenses; our ability to fund our operating plans with our current cash, cash equivalents, and investments; our ability to maintain undisrupted business operations due to the COVID-19 pandemic; unstable market and economic conditions having serious adverse consequences on our business, financial condition and stock price; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2021, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact: Joyce Allaire LifeSci Advisors, LLC jallaire@lifesciadvisors.com
So far into the year, healthy demand and strong pricing for Equity Residential's (EQR) properties have aided revenue growth. However, rents are likely to moderate from here on due to seasonality.
The main point of investing for the long term is to make money. Better yet, you'd like to see the share price move up...
Recently, Zacks.com users have been paying close attention to Equinor (EQNR). This makes it worthwhile to examine what the stock has in store.
The FDA offered mixed messages Friday for Amylyx Pharmaceuticals' experimental neurological treatment, and shares crashed.
The CDC green-lighted updated Covid booster shots from Pfizer with BioNTech and Moderna, but vaccine stocks largely dipped Friday.
China granted emergency use authorisation to Livzon Pharmaceutical Group Inc's COVID-19 vaccine as a booster, the company said on Friday, one of just two new products against the disease the country has cleared in more than a year. Livzon's vaccine, based on the original coronavirus, if rolled out to the general public would widen booster options for China's 1.4 billion population, of which 90% have been vaccinated and nearly 60% have received a booster dose. The United States has authorised updated COVID-19 booster shots from Pfizer/BioNTech and Moderna that target the BA.4 and BA.5 Omicron subvariants, while countries, including Canada and the UK, also have ordered updated Omicron vaccine boosters for campaigns later this year.
Do you have trouble focusing or completing tasks? Or do you ever feel restless or fidgety and can’t seem to stop? These are common signs of ADHD. You may find this surprising if you don’t have an official ADHD diagnosis, but as it turns out, many adults have been living with ADHD and don’t recognize […]
It's not just COVID
The 84-year-old actor and activist said she has started chemotherapy, but that she wouldn't let her treatment stop her from organizing around climate change.View Entire Post ›
Global conference to focus on advancing the life-saving impacts of genomic health care
Parade.com has an extensive editorial partnership with Cleveland Clinic, consistently named as one of the nation's best hospitals in U.S. News & World Report's annual "America's Best Hospitals" survey. Click here to learn more about our health reporting policies. Taking diet pills, exercising ...
The Oklahoma Health Department preordered supplies of the updated COVID-19 vaccines, which could arrive in the state as soon as Tuesday.
The debate on whether to label MPV a "sexually transmitted disease" that affects mostly "gay and bi men" rages on.
Pfizer (PFE) /BioNTech (BNTX) and Moderna (MRNA) get positive CHMP opinion for Omicron-targeting bivalent booster.
A former ShorePoint Health Venice employee filed the lawsuit Aug. 29 — on behalf of herself and approximately 600 other employees — alleging CHS and the hospital violated the Worker Adjustment and Retraining Notification Act.
Jane Fonda has been diagnosed with Non-Hodgkin lymphoma.
The European Medicines Agency (EMA) on Thursday backed the use of Novavax's COVID-19 shot as a booster for adults, ahead of an anticipated rise in infections this winter. The vaccine, Nuvaxovid, is designed to target the strain of the virus that originally emerged in China. The EMA's recommendation is for people who previously were inoculated with either the Novavax shot, or any other COVID vaccine.
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Exebacase Active in Rabbit Model of MRSA Implant-Associated Osteomyelitis On July 15, 2022, ContraFect Corp. (NASDAQ:CFRX) announced the publication of results in the Journal of Bone and Joint Infection from a preclinical rabbit model of implant-associated methicillin-resistant Staphylococcus aureus (MRSA)
A smoked salmon product sold in 10 states is being recalled after a sample tested positive for Listeria. The recall concerns 4-oz. packages of St.
The 84-year-old actress is currently undergoing chemotherapy. Jane Fonda Diagnosed with Lymphoma Alex Young